Cory Abate-Shen

Cory Abate-Shen


Michael and Stella Chernow Professor of Urological Oncology

Chair, Department of Pharmacology


Department of Pathology and Cell Biology
Department of Systems Biology
Center for Cancer Systems Therapeutics

Administrative Coordinator:
Rachel Kelly

Cory Abate-Shen is chair of Columbia's Department of Pharmacology, professor in the Department of Urology and Department of Pathology and Cell Biology, and the Michael and Stella Chernow Chair of Urological Oncology. She is investigating the molecular mechanisms of homeobox genes in development and cancer. Her laboratory has provided groundbreaking insights on the molecular bases of how homeoproteins achieve target gene recognition in vivo. She has also developed mouse models of prostate cancer that have been widely used to investigate the molecular bases of prostate tumorigenesis and as preclinical models for intervention and therapy. She has been the recipient of several awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and the Women in Cell Biology Junior Award from the American Society for Cell Biology. She is the principal investigator on five federal grants including an NCI consortium grant on Mouse Models of Human Cancer. In addition, she has received funding from several other sources including the March of Dimes, the New Jersey Commission on Cancer Research and the Gustave and Louise Pfeiffer Research Foundation. She has recently been named an American Association of Cancer Research Professor.

More News


Dr. Cory Abate-Shen Named Chair of Pharmacology at Columbia
Cory Abate-Shen, PhD, known for her leading work in the development of innovative mouse models for translational research in prostate and bladder cancers, has been named chair of the Department of Pharmacology at Columbia's Vagelos College of Physicians and Surgeons. Her appointment will be effective April 1, 2019. Dr. Abate-Shen is the Michael and Stella Chernow Professor of Urologic Sciences at Columbia and holds joint appointments in the Departments of Systems Biology, Medicine and Pathology & Cell Biology, and is former interim director of the Herbert Irving Comprehensive Cancer Center.
Prostate Cancer Grant Spotlights Columbia’s Aim to Deliver Precision Cancer Medicine
Columbia University Irving Medical Center experts in prostate cancer will lead a new team research project that tests a novel approach for personalized cancer treatment. The two-year project, funded by a $1 million Challenge Award from the Prostate Cancer Foundation, combines computational methods for targeted drug therapy, single-cell RNA sequencing and novel cancer immunotherapy. The combined approaches are behind a proof-of-concept clinical trial for patients at Bronx VA with lethal metastatic prostate cancer.
Dr. Cory Abate-Shen Elected an AAAS Fellow
The American Association for the Advancement of Science has elected Dr. Cory Abate-Shen a 2018 Fellow, recognizing her work in the development of innovative mouse models to better understand how basic cellular mechanisms are co-opted in cancer and for her contributions to the field of cancer biology. A leader in genitourinary malignancies, Dr. Abate-Shen is particularly interested in advancing our understanding of the mechanisms and modeling of prostate and bladder tumors. She holds joint appointments in the Departments of Systems Biology, Medicine and Pathology & Cell Biology.
Columbia Team Awarded New Prostate Cancer Grant for Innovative Precision Cancer Research
The Prostate Cancer Foundation (PCF) has announced more than $5.5 million in research funding to six new 2018 PCF Challenge Award teams, including an interdisciplinary team at Columbia University Irving Medical Center. The Columbia team includes Systems Biology faculty Drs. Michael Shen, Andrea Califano and Cory Abate-Shen, with several leading investigators from the Herbert Irving Comprehensive Cancer Center, the James J. Peters Veterans Affairs Medical Center and Dana-Farber Cancer Institute.
Michael Shen Wins Cancer Research Innovation Award
The Bladder Cancer Advocacy Network has awarded Professor Michael Shen, PhD, the 2018 Bladder Cancer Research Innovation Award. The honor singles out scientists whose creative, novel research has great potential to advance therapies for bladder cancer, the fifth most common cancer in the U.S.